As the year comes to a close, it’s normal for CEOs to reflect on the preceding 12 months. This is a special time in the history of Egnyte, so this look-back can only be done with the additional perspective of the past 12 years, as well as a look forward to 2020.
Data is the lifeblood of the life sciences. As therapeutics, medical devices, and diagnostics advance from early-stage development into clinical testing and beyond, the scrutiny of reported data and procedures dramatically increases. Dating back to the 1990s, many pharmaceutical and biotech companies have implemented systems and processes to store, exchange, and analyze regulated data from environments governed by GxP (e.g, clinical trials, manufacturing, toxicology, etc.).
No one is a stranger to the notion of security. We protect our homes and physical assets with locks and cameras and are vigilant when we encounter abnormal behavior. But for some reason, the data entrusted to us is not always given the same type of protection. That data has become a prime target for cybercriminals which is manifested in the form of ransomware attacks, which are increasingly prevalent.
